Radiopharm Theranostics Ltd (RADX) Form 6-K — Oct 26, 2026
Radiopharm Theranostics (Nasdaq: RADX) received $8,000,000 from Rockford Capital under a funding facility secured against its anticipated FY26 Australian R&D Tax Incentive. The facility charges interest at a commercial rate, with repayment due by October 26, 2027 and no penalty for early repayment, giving the clinical-stage radiopharmaceutical developer early access to cash it expects from the Australian Taxation Office. Proceeds will fund the company's clinical trial pipeline (one Phase 2 and five Phase 1 trials in solid tumors) and general working capital.
Key figures
- Debt Amount
- 8000000
- Maturity Date
- 2027-10-26
- Early repayment
- can be repaid at any time without penalty prior to maturity
- Facility lender
- Rockford Capital
- Rdti refundable tax offset rate
- up to 43.5%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.